Preeclampsia pregnancy toxicosis
Conditions
Interventions
None listed
Sponsors
Leids Universitair Medisch Centrum
Eligibility
Inclusion criteria
Inclusion criteria: Women who conceived through IVF/ICSI with donated oocytes or autologous oocytes, women who conceived after embryo donation, women with surrogacy pregnancy, and women with spontaneously conceived pregnancies.
Exclusion criteria
Exclusion criteria: Subjects that are mentally or legally incapable or with known chromosomal abnormalities (e.g. Turner XO syndrome) will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical outcome (e.g. pregnancy complications, such as miscarriage and preeclampsia) is studied in relation to the level of immunogenetic differences between mother and child. | — |
Secondary
| Measure | Time frame |
|---|---|
| Several aspects of the innate and cellular immune response (such as complement factors, cytokine profile and cell phenotyping) in respect to clinical outcome and pregnancy complications. Secondary study parameters, mainly relevant for this amendment include: - The association of a high number of fetal-maternal HLA mismatches, and the severity and time to development of pre-eclampsia in OD pregnancies. - The association of age, parity, multiple gestation, ethnicity and other factors on the development of preeclampsia in OD pregnancies. - The prognostic effect of other factors (such as age, indication of OD, etc.), including level of HLA mismatches, on the development of preeclampsia in OD pregnancies. - To develop a prediction model to predict development of hypertensive disease during OD pregnancy. | — |
Countries
Netherlands
Contacts
Public ContactMLP van der Hoorn
Leids Universitair Medisch Centrum
Outcome results
None listed